Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.74 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.69 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.69 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.69 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.69 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.67 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403436 | 0.90 | CCR3 (0.75) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| Hydrochloric Acid SCHEMBL7026911 | 0.88 | CCR3 (0.73) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| SCHEMBL7409408 | 0.87 | SIGMAR1 (0.91) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| SCHEMBL7374609 | 0.85 | SIGMAR1 (1.00) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| Hydrochloric Acid SCHEMBL7404260 | 0.85 | SIGMAR1 (0.88) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| SCHEMBL3102949 | 0.85 | CARM1 (0.82) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| SCHEMBL7247832 | 0.85 | CCR3 (0.72) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| SCHEMBL8927885 | 0.85 | CCR3 (0.72) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| SCHEMBL153896 | 0.85 | KCNH2 (0.88) | CCR3SIGMAR1TMEM97KCNH2CARM1 | |
| SCHEMBL5888823 | 0.84 | SIGMAR1 (1.00) | CCR3SIGMAR1TMEM97KCNH2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567495-A4 | SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS | HARVARD COLLEGE (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060159617-A1 | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-07-20 | — | — | US | disclosed |
| EP-1567495-A2 | SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004043380-A2 | SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1180513-A1 | CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| CN-1148853-A | Alkylenediamine derivatives | NIPPON CHEMIPHAR CO (JP) | 1997-04-30 | — | — | CN | disclosed |
| EP-0753514-A1 | ALKYLENEDIAMINE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0040793-B1 | NOVEL QUINAZOLINE-DIONE COMPOUNDS, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | Ishikawa, Masayuki (JP) | 1985-08-28 | — | — | EP | disclosed |
| US-4405623-A | HYPOTENSIVE AGENTS, VASODILATORS | MASAYUKI ISHIKAWA (JP) | 1983-09-20 | — | — | US | disclosed |
| EP-0040793-A1 | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof | Ishikawa, Masayuki (JP) | 1981-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159617-A1 | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors | SSTR5, SSTR1, SSTR3 | CCR3 368/4885SIGMAR1 304/4885TMEM97 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.